


## Immuneel Therapeutics inks new partnerships to improve financial access to CAR T-cell therapy in India

08 January 2026 | News

### Immuneel Therapeutics has entered into partnerships with Impact Guru and CarePal Money



Addressing one of the most persistent barriers to advanced cancer care in India, Bengaluru-based Immuneel Therapeutics has recently announced strategic partnerships with Impact Guru, a leading healthcare crowdfunding platform, and CarePal Money, a healthcare-focused lending marketplace. The collaborations aim to significantly improve financial access to CAR T-cell therapy for patients across diverse socio-economic backgrounds.

CAR T-cell therapy is among the most advanced and personalised treatments available today for certain blood cancers, offering renewed hope to patients with relapsed or refractory disease. However, access to these therapies has been constrained by high upfront costs and limited financing options. Through this integrated access model, Immuneel seeks to address a core challenge facing advanced therapies in emerging markets: affordability and financial preparedness.

Under the partnership, Impact Guru will enable patients and families to raise funds through its digital crowdfunding platform, mobilising community support via donation campaigns and awareness drives backed by a donor network of over 50 lakh contributors. CarePal Money will facilitate structured credit solutions by connecting eligible patients with its network of NBFC partners, offering tailored loan and financing options for medical treatment. Immuneel Therapeutics will continue to deliver globally benchmarked CAR T-cell therapies in India, while working closely with both partners to ensure timely financial support alongside clinical care.

The collaboration represents a scalable access framework for emerging markets, where medical advances must be matched with sustainable financing solutions. By integrating advanced cell and gene therapies with digital crowdfunding and structured healthcare lending, the partners aim to complement public health systems, insurance coverage, and future reimbursement pathways for CAR T-cell therapy. As these treatments become more integral to modern oncology, the partnership signals a shift towards ecosystem-led healthcare delivery, where innovation, financing, and policy objectives converge to improve patient outcomes at scale.